RE: Explosive Upside here24 Feb 2023 10:03
Lots of positive waffle there MP.
Its a Stock pickers market. GDR is well positioned. - No, GDR was well positioned when the sp was at or below about 12p. Now it's positioned precariously sp wise because everyone knows we're about to be hit with another fund raise and have nothing guaranteed or sold yet
Genedrive over the years through cutting edge scientific innovation have repeatedly produced tests with fastest results turnaround times. - And sold almost nothing.
Genedrive has a strong edge in a niche market with AIHL tests. No competition. -Yes, but still no contracts announced to sell anything. GDR needs funds to get manufacture of AIHL in place and ready to go. As for competition, there may not be any yet but you can be 100% certain that given the potential global market and money to be made someone somewhere will already be beavering away trying to develop and then sell their own products. We just have to hope none of the big pharmas are already on this as they would be able to get their products to market far quicker and easier than GDR, especially if it's a really well established pharma with existing relationships in the industry in all territories.
Even stroke marker test (currently also with NICE) produces results within an Hour. - Long way off from making it to market 12 months ? We need funding to get AIHL manufactured and to market first. it will take time to see income from AIHL come into GDR coffers and enable the Stroke Marker Testing kits to be on the shelves too.
For AIHL, Genedrive will set the market with ever growing demand for quick results from the Pharma Healthcare industry. Margins can be very lucrative when you are the only supplier. Just get your Sales team and Distributors active. - GDR's sales team is utterly hopeless and to date have had almost zero success selling any products, even a fab Covid PoC testing kit in a global pandemic. 'Get them active...'? Really, is that why they've failed thus far?
Stroke tests will be next. - Yes, in time but far more likely 2024 than 2023.
i essentially agree with you just trying to balance some of the ramping. Much as a I want GDR to do well I don't want to see yet another of those massive spikes in which investors get trapped for years whilst Budd and Gilham flounder about trying to get little piggy to market. It will come good but people need imho to be realistic and above all to be patient.
My personal hope is that a big pharma will have already begun talks with Gilham saying look you run the risk of failure if you try and do this on your own. We will ensure GDR's product success but sell the whole shebang to us for ..... answers on a postcard. Without any funding in place Gilham is in a weak position so expect this to be dealt with very soon after end of March. It may knock us back a bit sp wise but once sorted and with full NICE recommendation I think discussions may become far more serious and we could be on the end of a nice and extremely s